Injectable Therapies and Their Effects on Reducing Chronic Inflammation in Diseases such as Obesity, Cancer and Type 2 Diabetes

Low-grade chronic inflammation is a central factor in the pathogenesis of obesity, cancer and type 2 diabetes (T2D) [1, 2]. This article explores an integrated therapeutic strategy, administered by injectable route, that combines dimethyl sulfoxide (DMSO), coenzyme Q10 (CoQ10), alpha-lipoic acid (ALA), curcumin, glutathione (GSH) and mimetics of microRNA‑146a (miR-146a) [3]. Injectable administration optimizes the bioavailability and tissue targeting of these agents, which act synergistically through anti-inflammatory, antioxidant and metabolic-modulating mechanisms [4, 5]. The primary focus lies on the role of miR-146a in regulating the IRAK1 and TRAF6 signaling pathway, crucial for immunometabolic homeostasis [6, 7]. This multidimensional approach has the potential to modulate chronic inflammation, optimize mitochondrial function and restore metabolic balance, representing a new frontier in the treatment of chronic inflammatory diseases [8, 9]. Additionally, the article delves into modulation of leptin resistance and compares this integrated approach with the most effective weight-loss strategies.